Below is the 2nd Valeureux's Letter.
It tells the story of the meeting and the first steps of CXS Therapeutics and the Valeureux fund.
You can find the first letter here
https://www.valeureux.com/journal/lettre1-lhistoire-de-cxs-therapeutics--1er-episode
And if you haven't read it yet, start there.
Happy reading.
philip
Guillaume's deep scientific roots, his perspective and his attitude as a researcher convince me. This desire to find a solution to Parkinson's with balance and lucidity hits the mark. Besides that, they have been working together with Anthony for many years and are a first-rate pair.
The core of the operational team, Guillaume/Anthony/Nadine is highly scientific and complementary:
The resumes are strong and complement each other.
Welded, the team is based on a foundation of shared values claimed and lived. Their leitmotif: to do everything possible to provide therapeutic solutions to patients. Unfailing motivation, proven resilience, humility, sharpness, ambition, which translate into: that would be extraordinary - and why not? A team that thrives and knows why it is there.
Green flag planted.
Guillaume is also a very good communicator. Any project that needs to mobilize, federate, convince, this is a very good point that I note. Anthony is precise, both in the development of the materials and the visual identity. Nadine is picky and chooses words carefully. Things are fluid and promising.
Green flag planted.
In terms of entrepreneurship, Guillaume positions himself as an “apprentice”. He quickly assimilates a colossal amount of information and experiences from others. Talent, will, audacity: an alliance of choice.
Green flag planted.
Priority projects:
To date, the platform is much more advanced than expected last December, with results that have been described as impressive in a rare disease by the specialists to whom they were presented.
Two new patents are filed with new targeted pathologies. The path for CSX0003 is clarified with series of scheduled studies To go to phase II = in the clinical study patient in 18 months.
The advances were significant enough to decide to start the SAPPIENS fundraiser, which will eventually be the Parkinson subsidiary of CXS Therapeutics, and which will carry the development of the drug candidate as far as necessary until a pharmaceutical laboratory takes over.
An international biotech fund will certainly be the next step in this path, to finance phase II. The fund
Of course, Valeureux keeps an eye on current research, each drug development is part of a context that is, and we are delighted, evolving.
Drug repositioning, mentioned in the first
Letter, is a particular sector in biotechs:
So many elements that reduce uncertainty, development time, and associated costs.
Patient associations and foundations are very present in the project:
France Parkinson, Parkinson Europe, Cure Parkinson... They challenge scientific hypotheses, provide a methodological guide for setting up clinical trial protocols, and open us up to support programs.
Also in contact with https://parkinson.network/
We are careful about communicating with patients. This potential treatment is promising, and yes, it's worth it to go test it out and go as far as possible in the best possible conditions to give it a full chance.
But on the other hand, it's not about creating expectations — on the contrary, you shouldn't wait, You have to take care of yourself with what is available.
The first round - 400,000 euros in 2023 for CXS Therapeutics - is a projection that translates a project into slides.
We tell our story, we explain our ambitions, the path we have traveled and still have to go, our first victories, our goals.
The numbers for the years to come are set to music.
We talk about this futurization with its share of beliefs and hypotheses.
Financial and operational scenarios are developed accordingly.
During this first moment of truth, I see the importance of the subject. A considerable number of people have never invested in a startup before.
It is an opportunity for multiple meetings, even of people who will not participate in the survey, but who can interact in other ways.
At that time, we were joined by Gabrielle Gache, a Swiss specialist in licensing and market access.
It complements the founders' team: a valuable reinforcement.
A few figures to close and give voice to this second round in progress.
Les €10,000 invested in December are valued today 35.290€.
This is therefore what you would have to invest in September 2024 to have the same number of shares as in December 2023.
Already a great difference!
It is planned a 5-year appointment clause = in just over 4 years for those who invested in December.
At that point, if there was no liquidity event before — the founders committed to doing their utmost to find a liquidity solution for early investors.
This is where the second letter ends.
The next, the third and the last in this series on CXS Therapeutics will be in your inbox on Tuesday, October 1st.
Do not hesitate to share this one with those who may be interested.
CXS/SAPPIENS is a well-advanced, extremely ambitious project, with the aim of creating the first etiological/neuroprotective (and therefore revolutionary) treatment for Parkinson's disease... and that's not all, as you may have read. Potential colossal impact in the crosshairs. So if you want to embark on this crazy adventure, This is where it happens.
